Natto-K™ is a proprietary blend containing the enzyme Nattokinase NSK-SD, which has been shown to have a high fibrinolytic activity (breaks down fibrin) and antioxidant activity. Nattokinase has been the subject of 17 studies, including two small human trials. Researchers from JCR Pharmaceuticals, Oklahoma State University, and Miyazaki Medical College tested nattokinase on 12 healthy Japanese volunteers (6 men and 6 women, between the ages of 21 and 55). The tests indicated that the natto generated a heightened ability to support circulation. On average, the volunteers” ELT (a measure of how long it takes to dissolve a blood clot) dropped by 48 percent within two hours of treatment. An additional study showed a 11% decrease in blood pressure after just two weeks.